Literature DB >> 8636965

Protective activity of a murine monoclonal antibody against acute and chronic experimental infection with type IV group B streptococcus.

M L Ricci1, C von Hunolstein, M J Gomez, L Parisi, L Tissi, G Orefici.   

Abstract

A murine IgM monoclonal antibody (MAb H11) was developed against the type polysaccharide capsular antigen of group B streptococcus (GBS), serotype IV, after intraperitoneal immunisation of BALB/c mice with heat-killed bacteria. MAb H11 reacted in immunodiffusion with the purified polysaccharide in both its sialylated and desialylated form, giving a line of identity, and opsonised type IV GBS strains in an in vitro assay. When administered at the time of intraperitoneal lethal challenge with homologous GBS, or 4 h earlier, MAb H11 protected 90% of the mice. Protection was still observed when MAb H11 was given 4 h after the challenge. This MAb was strongly effective in preventing septic arthritis induced by type IV GBS.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8636965     DOI: 10.1099/00222615-44-6-475

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  3 in total

Review 1.  Recognition and management of bacterial arthritis.

Authors:  M A Cimmino
Journal:  Drugs       Date:  1997-07       Impact factor: 9.546

2.  Toll-like receptor 2 deficiency is associated with enhanced severity of group B streptococcal disease.

Authors:  Manuela Puliti; Satoshi Uematsu; Shizuo Akira; Francesco Bistoni; Luciana Tissi
Journal:  Infect Immun       Date:  2009-01-29       Impact factor: 3.441

3.  CpG-DNA induces bacteria-reactive IgM enhancing phagocytic activity against Staphylococcus aureus infection.

Authors:  Te Ha Kim; Dongbum Kim; Heesu Lee; Min Hyung Kwak; Sangkyu Park; Younghee Lee; Hyung-Joo Kwon
Journal:  BMB Rep       Date:  2019-11       Impact factor: 4.778

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.